OPTI.GB OptiBiotix Health plc

TIDMOPTI

RNS Number : 2904H

OptiBiotix Health PLC

26 July 2023

26 July 2023

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

Result of AGM

Directorate Change

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care a nnounces that at the AGM held earlier today, all resolutions were duly passed.

Further to the announcement of 28 June 2023, the Company confirms that Non-executive Directors Stephen Hammond and Chris Brinsmead have not put themselves for re-election as Directors and have therefore, with immediate effect, ceased to be Directors of the Company.

Neil Davidson, Chairman of OptiBiotix Health plc commented: "I would like to take this opportunity to offer our thanks to Chris Brinsmead and Stephen Hammond for their respective contributions and wise counsel during their time on the Board."

The full voting results will be available on the website in due course here: https://www.optibiotix-ir.com/content/investors/

For further information, please contact:

 
  OptiBiotix Health plc                                    www.optibiotix.com 
  Neil Davidson, Chairman                          Contact via Walbrook below 
  Stephen O'Hara, Chief Executive 
 
  Cairn Financial Advisers LLP (NOMAD)                     Tel: 020 7213 0880 
  Liam Murray / Jo Turner / Ludovico Lazzaretti 
  Peterhouse Capital Limited (Broker)                      Tel: 020 7220 9797 
  Duncan Vasey / Lucy Williams 
 
  Walbrook PR Ltd                                          Mob: 07876 741 001 
  Anna Dunphy 
 
 
   About OptiBiotix   -   www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGRFMBTMTTTBLJ

(END) Dow Jones Newswires

July 26, 2023 07:34 ET (11:34 GMT)

OptiBiotix Health (AQSE:OPTI.GB)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024

OptiBiotix Health (AQSE:OPTI.GB)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024